Working… Menu

Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer (PARAGON-II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00844233
Recruitment Status : Completed
First Posted : February 16, 2009
Last Update Posted : March 29, 2013
Information provided by (Responsible Party):
Biocompatibles UK Ltd

Brief Summary:
The objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in the neoadjuvant treatment (i.e. the Irinotecan Bead is administered prior to surgery) of resectable liver metastases from colorectal cancer.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Device: Irinotecan Bead Phase 1 Phase 2

Detailed Description:

The Primary Endpoint of this study is Tumour resectability at surgery. Secondary Endpoints:

  1. Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0)
  2. Tumour response assessed by imaging (RECIST and necrosis)
  3. Viable residual tumour assessed by pathological evaluation of resected liver tissue.
  4. Recurrence (time and site) following resection
  5. Correlation of tumour response by imaging and pathology

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm Phase II Study of Neoadjuvant Therapy Using Irinotecan Bead in Patients With Resectable Liver Metastases From Colorectal Cancer
Study Start Date : February 2009
Actual Primary Completion Date : September 2011
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Irinotecan Bead
Device: Irinotecan Bead
Irinotecan eluting bead
Other Name: Irinotecan Bead, PARAGON Bead

Primary Outcome Measures :
  1. Tumour resectability at surgery [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. Safety assessed by SAE and AE monitoring (NCI CTCAE v3.0) [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  1. Presence of potentially resectable colorectal cancer liver metastases, with less than 60% liver tumour replacement. The consulting surgeon, according to local practice, will determine resectability.
  2. Patients having undergone complete resection of the primary tumour without gross or microscopic evidence of residual disease (R0), or the primary tumour is considered R0 resectable at screening.
  3. Age: 18-80 years.
  4. ECOG Status ≤2.
  5. No previous irinotecan-containing chemotherapy for advanced disease.
  6. Previous chemotherapy is allowed (unless it contained irinotecan), but must have ended at least one month prior to study entry.
  7. Presence of adequate contraception in fertile (M/F) patients. Pregnant or lactating women are excluded.
  8. Absence of any other previous malignancy other than adequately treated in situ carcinoma of the cervix or non-melanoma skin cancer (unless there has been a disease-free interval of at least 10 years).
  9. Patients should not have participated in another clinical trial with any investigational drug in the 30 days prior to enrolment.
  10. Absence of:

    • Peripheral neuropathy (CTC > grade 1)
    • Uncontrolled congestive heart failure or angina pectoris, or hypertension or arrhythmia.
    • History of significant neurologic or psychiatric disorders
    • Active infection
  11. Written informed consent according to ICH/EU GCP, and any applicable local, national or international regulations.
  12. Patients with liver-dominant disease, defined as ≥80% of the tumour body burden confined to the liver. Unilobar disease, or bilobar disease suitable for treatment in a single chemoembolisation procedure, with a maximum of 4 lesions.
  13. Hematologic function: WBC ≥3.0 x 10*9/L, platelets ≥100 x 10*9/L, Absolute neutrophil count > 1.5 x 10*9/l.
  14. Adequate organ function as measured by:

    1. Serum creatinine ≤2 x upper limit of normal (ULN).
    2. Serum transaminases (AST & ALT) ≤5 x ULN.
    3. Total bilirubin ≤1.5 x ULN.
    4. Prothrombin time >50% of normal.

Exclusion criteria

  1. Extrahepatic metastases constituting >20% of tumour body burden.
  2. Contraindications to irinotecan:

    1. Chronic inflammatory bowel disease and/or bowel obstruction.
    2. History of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate.
    3. Severe bone marrow failure.
    4. Concomitant use with St John's Wort.
  3. Active bacterial, viral or fungal infection within 72 hours of study entry.
  4. Allergy to contrast media that cannot be managed with standard care.
  5. Any contraindication for hepatic embolisation procedures:

    1. porto-systemic shunt.
    2. hepatofugal blood flow.
    3. severe atheromatosis.
  6. Contraindication to hepatic artery catheterisation, such as a patient with severe peripheral vascular disease precluding catheterisation.
  7. Other significant medical or surgical condition, or any medication or treatment regimens, that would place the patient at undue risk, that would preclude the safe use of chemoembolisation or would interfere with study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00844233

Layout table for location information
Medical University Vienna, AKH
Vienna, Austria, 1090
Centre Hépato-Biliaire, Hôpital Paul Brousse
Villejuif, France, 94804
United Kingdom
Basingstoke and North Hampshire NHS Foundation Trust
Basingstoke, United Kingdom, RG24 9NA
University Hospital Aintree
Liverpool, United Kingdom, L9 7AL
North Manchester General Hospital
Manchester, United Kingdom, M8 5RB
Sponsors and Collaborators
Biocompatibles UK Ltd
Layout table for investigator information
Principal Investigator: Professor Graeme Poston, MB, MS, FRCS Consultant General Surgeon

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Biocompatibles UK Ltd Identifier: NCT00844233     History of Changes
Other Study ID Numbers: CA1016
First Posted: February 16, 2009    Key Record Dates
Last Update Posted: March 29, 2013
Last Verified: September 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents